SLC25A18: A promising drug target for glutamate/H(+) symporter 2 in neurodegenerative diseases

Target Name: SLC25A18

NCBI ID: G83733

SLC25A18

SLC25A18: A promising drug target for glutamate/H(+) symporter 2 in neurodegenerative diseases

Glutamate and its role in neurotransmission have been extensively studied in the context of neurological disorders. In neurodegenerative diseases, glutamate homeostasis is often disrupted, leading to an imbalance in the levels of neurotransmitters, including glutamate. The neurotransmitter glutamate plays a crucial role in the regulation of neuronal excitability and synaptic plasticity. The protein SLC25A18, which belongs to the family of glutamate/H(+) symporters, has been identified as a potential drug target in neurodegenerative diseases.

SLC25A18 function

SLC25A18 is a protein that is expressed in various tissues, including brain, heart, and kidney. It is a member of the SLC family, which includes several subfamilies, including the SLC25 family. The SLC25A18 gene encodes a protein that has four known isoforms: SLC25A18, SLC25A20, SLC25A30, and SLC25A40. These isoforms differ in their N- and C-terminus, as well as their level of expression in different tissues. SLC25A18 is predominantly expressed in the brain and is also found in heart and kidney.

SLC25A18 is a transmembrane protein that functions as a glutamate/H(+) symporter. Glutamate is a highly potent neurotransmitter that plays a crucial role in cell signaling, including neurotransmission. The H(+) symporter is a protein that helps maintain the intracellular concentration of H+ ions, which are involved in various cellular processes, including neurotransmission. SLC25A18 functions as a co-transporter for the neurotransmitter glutamate and helps regulate its intracellular concentration.

SLC25A18 is involved in various cellular processes, including neurotransmission, cell signaling, and neuroprotection. It is involved in the regulation of neurotransmitter release from axon terminals, which is critical for the transmission of signals in the nervous system. SLC25A18 is also involved in the regulation of neurotransmitter uptake and release from dendrites, which is critical for the regulation of neuronal excitability.

SLC25A18 is also involved in the regulation of ion channels, including the voltage-dependent K(+) channels. These channels are critical for the regulation of neuronal excitability and play a role in neurotransmission. SLC25A18 is also involved in the regulation of the production of reactive oxygen species (ROS), which can damage cellular components and contribute to the development of neurodegenerative diseases.

Drug targeting SLC25A18

SLC25A18 is a potential drug target in neurodegenerative diseases due to its involvement in various cellular processes that are disrupted in these conditions. Drugs that target SLC25A18 have been shown to improve neurotransmission and protect against neurodegeneration in various models of neurodegenerative diseases.

One of the main classes of drugs that have been shown to target SLC25A18 is the rapamycin family of drugs. Rapamycin is an inhibitor of the mTOR pathway, which is involved in cell growth and survival. SLC25A18 is a target of rapamycin, and drugs that inhibit SLC25A18 have been shown to improve neurotransmission and protect against neurodegeneration in various models of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Another class of drugs that have been shown to

Protein Name: Solute Carrier Family 25 Member 18

Functions: Responsible for the transport of glutamate from the cytosol into the mitochondrial matrix with the concomitant import of a proton (symport system)

The "SLC25A18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets